Screener
Stoke Therapeutics, Inc. STOK Deferred Revenue
Deferred Revenue at other companies
Other financials
Where this comes from
Reported directly by Stoke Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:DeferredRevenueNoncurrent.
The source filing: Stoke Therapeutics, Inc.’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 4:06 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-211874
| Line item | March 31, 2026 | December 31, 2025 |
|---|---|---|
| Accrued and other current liabilities | 23,901 | 41,035 |
| Deferred revenue - current portion | 10,066 | 11,901 |
| Total current liabilities | $40,806 | $57,875 |
| Deferred revenue - net of current portion | 6,603 | 6,961 |
| Other long-term liabilities | 991 | 1,141 |
| Total long-term liabilities | 7,594 | 8,102 |
| Total liabilities | $48,400 | $65,977 |
| Commitments and contingencies (Note 6) |
Item 1. Financial Statements.
FAQ
- What is Stoke Therapeutics, Inc.'s deferred revenue?
- Stoke Therapeutics, Inc. (STOK) reported deferred revenue of $6.6M in Q1 2026.
- How has Stoke Therapeutics, Inc.'s deferred revenue changed year-over-year?
- Stoke Therapeutics, Inc.'s deferred revenue decreased by 35.6% year-over-year, from $10.26M to $6.6M.
- What is the long-term trend for Stoke Therapeutics, Inc.'s deferred revenue?
- Over 2 years (2022 to 2025), Stoke Therapeutics, Inc.'s deferred revenue has grown at a -56.5% compound annual growth rate (CAGR), from $36.86M to $6.96M.
- What does deferred revenue mean?
- Payments received from customers for goods or services to be delivered within one year — recognized as revenue as performance obligations are satisfied.
Ask your AI about Stoke Therapeutics, Inc.'s deferred revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude